These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1585 related articles for article (PubMed ID: 19148531)

  • 1. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
    Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
    Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
    Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.
    Park SR; Oh DY; Kim DW; Kim TY; Heo DS; Bang YJ; Kim NK; Kang WK; Kim HT; Im SA; Suh JH; Kim HK; Kim HK
    Oncol Rep; 2004 Nov; 12(5):1059-64. PubMed ID: 15492793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
    Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
    Bokemeyer C; Hartmann JT; Lampe CS; Clemens MR; Quietzsch D; Forkmann L; Kanz L
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-96-S19-100. PubMed ID: 9427277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
    Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
    Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
    Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; J├Ąger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
    Kim JG; Sohn SK; Song HS; Kwon KY; Do YR; Lee KH; Hyun MS; Ryoo HM; Bae SH; Park KU; Baek JH; Lee WS; Chung JS; Cho GJ; Sohn CH; Jang JS; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):863-9. PubMed ID: 17333192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
    Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
    Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer.
    Nagata N; Kimura M; Hirabayashi N; Tuburaya A; Murata T; Kondo K; Fukuda Y; Kobayashi M; Miyashita Y; Nakao A; Sakamoto J
    Hepatogastroenterology; 2008; 55(86-87):1846-50. PubMed ID: 19102406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
    J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.